NCT06155994View on ClinicalTrials.gov

68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Neuroendocrine Tumors
Interventions
DRUG

68Ga-DOTA-MGS5

intravenous administration

Trial Locations (1)

6020

Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Medical University Innsbruck

OTHER

NCT06155994 - 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours | Biotech Hunter | Biotech Hunter